Only four months after approval of its intravenous drug Vyvgart (efgartigimod) for generalized myasthenia gravis (gMG), argenx N.V. is forecasting that the vast majority of patients who are candidates for treatment eventually may switch to the subcutaneous formulation after a successful Phase III clinical trial.
The company announced topline data on 22 March from the 110-patient ADAPT-SC study of subcutaneous efgartigimod in gMG, showing that the trial reached its primary endpoint of showing statistical non-inferiority compared with intravenous Vyvgart in terms of total immunoglobulin G (IgG) reduction from baseline at day 29. Secondary endpoints also showed improvement consistent with the I.V. drug